Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SQY51 in Duchenne Muscular Dystrophy
NCT05753462Phase 2Recruiting
- Sponsor
- SQY Therapeutics
- Start
- Apr 2023
- Primary completion
- Feb 2025
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of SQY51 in Duchenne muscular dystrophy (DMD), sponsored by SQY Therapeutics. Started Apr 2023; status: recruiting.
02
Drugs
SQY51
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT05753462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05753462.